tag immune-tolerance 
pharmaphorum
DECEMBER 12, 2022
Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – primary immune thrombocytopenia (ITP) – thanks to new data reported at the ASH annual meeting.
pharmaphorum
JANUARY 5, 2021
Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.
pharmaphorum
DECEMBER 23, 2022
In the last few years, the first generation of cell therapies has offered a powerful new way of treating blood cancers, with CAR-T technology reprogramming patients’ immune system to fight cancer. Treatment has been generally well-tolerated, with the majority of on-target toxicities being mild or moderate in severity.
Expert insights. Personalized for you.
52 
Let's personalize your content